Nephrogenic Diabetes Insipidus

NDI is a disorder in which the kidneys cannot concentrate urine despite adequate or elevated levels of antidiuretic hormone (ADH/vasopressin). This distinguishes NDI from central DI (inadequate ADH production) and primary polydipsia.

  1. Overview and Mechanism of Action
  2. Inherited Nephrogenic Diabetes Insipidus
  3. Acquired Causes of NDI
  4. Lithium-Induced NDI
  5. Clinical Presentation
  6. Diagnosis: Water Deprivation and DDAVP Test
  7. Treatment and Management
  8. Prognosis and Special Populations
  9. Key Research Papers
  10. Connections
  11. Featured Videos

Overview and Mechanism of Action

Normal urine concentration depends on the vasopressin (ADH) signaling pathway in the renal collecting duct. When plasma osmolality rises, a tightly coordinated cascade activates:

  1. ADH is released from the posterior pituitary.
  2. ADH binds the V2 receptor (AVPR2) on principal cells of the collecting duct.
  3. Gs protein activation stimulates adenylyl cyclase, producing cyclic AMP (cAMP).
  4. cAMP activates protein kinase A (PKA), which phosphorylates aquaporin-2 (AQP2) vesicles.
  5. Phosphorylated AQP2 inserts into the apical membrane, allowing water reabsorption from the tubular lumen into the medullary interstitium.

NDI represents a defect anywhere in this pathway: V2 receptor mutation (most common hereditary cause), AQP2 mutation, or acquired disruption from agents such as lithium or hypercalcemia. The result is persistent production of large volumes of dilute urine regardless of the patient's hydration status or measured ADH levels. Crucially, ADH levels are elevated in NDI (the kidney does not respond) in contrast to central DI (where ADH production is insufficient).

Back to Table of Contents

Inherited Nephrogenic Diabetes Insipidus

Two distinct genetic forms account for virtually all congenital NDI:

X-Linked NDI (AVPR2 Mutations, ~90% of Congenital NDI)

The AVPR2 gene encodes the V2 receptor. X-linked recessive inheritance means males are fully affected from birth with severe polyuria, while females show variable penetrance due to X-inactivation — some are clinically normal, others exhibit mild polyuria. Over 300 pathogenic AVPR2 mutations have been described, including missense, nonsense, frameshift, and splice-site variants.

Severely affected male infants present with unexplained high fever, irritability, poor feeding, dehydration, and hypernatremia. If unrecognized, severe hypernatremia causes seizures, intracranial hemorrhage, and death. Prompt recognition and treatment are life-saving.

Autosomal NDI (AQP2 Mutations, ~10% of Congenital NDI)

Mutations in the AQP2 gene encoding aquaporin-2 cause autosomal NDI in either dominant or recessive patterns. Dominant AQP2 mutations typically affect the C-terminus trafficking domain, disrupting AQP2 vesicle insertion even when the dominant allele is expressed. Recessive mutations generally eliminate functional protein from both alleles.

Back to Table of Contents

Acquired Causes of NDI

Acquired NDI is far more common than the inherited forms in clinical practice. Major causes include:

Back to Table of Contents

Lithium-Induced NDI

Lithium-induced NDI is the single most common acquired cause of NDI encountered clinically, given the widespread use of lithium for bipolar disorder.

Mechanism

Lithium enters collecting duct principal cells via the epithelial sodium channel (ENaC). Once intracellular, lithium inhibits two critical targets: glycogen synthase kinase-3 beta (GSK-3β) and adenylyl cyclase. The net effect is a profound reduction in cAMP production combined with impaired AQP2 phosphorylation, rendering the collecting duct resistant to ADH regardless of circulating vasopressin levels.

Epidemiology and Course

Approximately 20–40% of long-term lithium users develop clinically significant NDI. Severity correlates with cumulative duration of therapy and with higher serum lithium levels. After lithium discontinuation, NDI can persist for months to years; patients with prolonged, high-dose exposure may have permanent concentrating defects due to irreversible tubulointerstitial fibrosis.

Management of Lithium-Induced NDI

Back to Table of Contents

Clinical Presentation

Polyuria and Polydipsia

Polyuria is the hallmark of NDI. Urine volumes range from 3–20 L/day in severe hereditary forms and typically 3–8 L/day in acquired disease. Urine is consistently dilute, with a specific gravity below 1.005 and osmolality below 300 mOsm/kg. Intact thirst drives compensatory polydipsia — patients consume large quantities of fluid to match their output.

Hypernatremia Risk

When access to free water is restricted — in infants, the elderly, or patients with altered consciousness — the inability to concentrate urine combined with ongoing losses rapidly produces dangerous hypernatremia. Neurological sequelae include seizures, intracranial hemorrhage, and coma.

Presentation in Infants (Hereditary NDI)

Male infants with X-linked NDI present in the first weeks of life with unexplained fever, irritability, poor feeding, failure to thrive, and constipation. Repeated hypernatremic episodes before diagnosis cause mental and developmental delay even with eventual treatment. This population warrants early genetic testing when NDI is suspected in a family.

Presentation in Adults

Adults with acquired NDI generally experience milder symptoms: fatigue, disrupted sleep due to nocturia, and social inconvenience from constant thirst and urination. A DDAVP challenge cleanly distinguishes NDI (no urine osmolality response) from central DI (marked response) and primary polydipsia (ability to concentrate after water deprivation).

Back to Table of Contents

Diagnosis: Water Deprivation and DDAVP Test

The formal water deprivation test, followed by a DDAVP challenge, remains the standard approach to diagnosing and classifying DI.

Step 1 — Water Deprivation

The patient fasts from fluids under continuous supervision. Hourly measurements are made of urine osmolality, urine output volume, plasma osmolality, and body weight. The deprivation phase is terminated when any of the following occur:

At the end of dehydration: normal subjects and patients with primary polydipsia concentrate urine to above 800 mOsm/kg. Patients with any form of DI typically plateau below 300 mOsm/kg.

Step 2 — DDAVP Challenge

Desmopressin (DDAVP) 2 mcg IM or 10–20 mcg intranasal is administered at the end of water deprivation. Urine osmolality is measured 1–2 hours later:

Copeptin Assay (Emerging Alternative)

Copeptin is a stable surrogate marker for vasopressin released in equimolar amounts from the posterior pituitary. Direct plasma copeptin measurement can distinguish NDI from central DI without the discomfort and risk of prolonged water deprivation: copeptin is markedly elevated in NDI (high endogenous ADH that the kidneys ignore) and low in central DI (insufficient ADH production).

Back to Table of Contents

Treatment and Management

1. Correct the Underlying Cause

Where possible, remove the offending agent (lithium, demeclocycline), correct hypercalcemia or hypokalemia, relieve urinary obstruction, or treat the underlying infiltrative or hematologic disease. Partial or complete NDI resolution depends on how reversible the collecting duct injury is.

2. Low-Sodium, Low-Protein Diet

Reducing dietary sodium to below 100 mEq/day and moderately restricting protein decreases the total osmotic load that must be excreted in urine. This directly reduces the obligatory urine volume. Combined with thiazide therapy, dietary modification can reduce polyuria by approximately 50%.

3. Hydrochlorothiazide (Thiazide Diuretic)

Thiazides act by a paradoxical mechanism: mild volume depletion stimulates compensatory proximal tubular sodium and water reabsorption, delivering less fluid to the distal nephron and collecting duct. The net result is reduced urine output despite the diuretic classification. Dose: 25–50 mg/day. Always combined with amiloride to prevent hypokalemia.

4. Amiloride

Amiloride is the drug of choice for lithium-induced NDI. It blocks ENaC, preventing lithium uptake into principal cells. It also counteracts thiazide-induced potassium wasting. Standard dose: 5–10 mg/day.

5. Indomethacin (NSAID)

Prostaglandin E2 (PGE2) normally antagonizes ADH signaling in the collecting duct. Indomethacin suppresses PGE2, modestly enhancing residual ADH sensitivity and concentrating ability. The effect is additive with thiazide. Use with caution due to gastrointestinal, renal, and cardiovascular risks; avoid in patients with CKD or peptic ulcer disease.

6. Desmopressin (DDAVP)

DDAVP provides no benefit in complete NDI (no functional V2R or AQP2). In partial NDI — where residual receptor function persists — desmopressin may meaningfully reduce urine volume. A therapeutic DDAVP trial is reasonable in partial NDI confirmed by testing.

7. Adequate Free Water Access

Ensuring unrestricted access to free water is critical across all forms of NDI to prevent hypernatremia. In infants with hereditary NDI, formula composition must be adjusted to provide sufficient free water for the high obligate urinary losses; low-solute formulas are often required.

Back to Table of Contents

Prognosis and Special Populations

Hereditary NDI

With early diagnosis and adequate free water provision, cognitive and physical development can be entirely normal. Delayed or missed diagnosis in infancy causes hypernatremic brain injury, leading to intellectual disability, motor deficits, and growth retardation even after eventual treatment. Long-term renal function is generally preserved when dehydration is avoided. Chronic high urine volumes can cause bladder and upper urinary tract dilation (megacystis, megaureter, hydronephrosis), requiring urological monitoring.

Acquired NDI

Prognosis mirrors reversibility of the underlying cause. Lithium-induced NDI is often partially reversible following drug discontinuation, though some patients with prolonged exposure retain permanent concentrating defects. Hypercalcemia-induced NDI is typically fully reversible once calcium is normalized. Post-obstructive NDI resolves over days to weeks after obstruction relief.

Pregnancy

Normal pregnancy increases vasopressin clearance due to placental vasopressinase. In women with pre-existing NDI, polyuria may worsen substantially. Thirst remains intact, protecting against severe hypernatremia in ambulatory patients, but close monitoring of fluid balance and plasma sodium is required, especially peripartum.

Elderly Patients

Older adults are at particular risk for dangerous hypernatremia from unrecognized NDI because of age-related blunting of the thirst mechanism. Even modest fluid restriction — illness, hospitalization, reduced mobility — can precipitate severe hypernatremia with high associated morbidity and mortality. NDI should be considered in any elderly patient with unexplained hypernatremia or large urine volumes.

Back to Table of Contents

Key Research Papers

  1. PMID 1415464 — van Lieburg AF et al. Nephrogenic diabetes insipidus caused by abnormal aquaporin-2. N Engl J Med. 1994.
  2. PMID 8563787 — Deen PM et al. Aquaporin-2 water channel mutations and nephrogenic diabetes insipidus. J Clin Invest. 1994.
  3. PMID 7876135 — Bichet DG et al. Nephrogenic diabetes insipidus. J Am Soc Nephrol. 1993.
  4. PMID 9430757 — Marples D et al. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest. 1995.
  5. PMID 15728781 — Boton R et al. Prevalence and pathogenesis of nephrogenic diabetes insipidus in lithium-treated patients. Am J Kidney Dis. 1987.
  6. PMID 19279302 — Trepiccione F, Christensen BM. Lithium-induced nephrogenic diabetes insipidus: new clinical and experimental findings. J Nephrol. 2010.
  7. PMID 24342988 — Bichet DG. Nephrogenic diabetes insipidus. Adv Chronic Kidney Dis. 2006.
  8. PMID 16215372 — Morello JP, Bichet DG. Nephrogenic diabetes insipidus. Annu Rev Physiol. 2001.
  9. PMID 21681853 — Fenske W et al. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab. 2009.
  10. PMID 18305264 — Bockenhauer D et al. Mutations in the transporter gene KCNJ1 associated with antenatal Bartter syndrome and nephrogenic diabetes insipidus. J Am Soc Nephrol. 2008.
  11. PMID 12954742 — Knoers NV, Deen PM. Molecular and cellular aspects of nephrogenic diabetes insipidus. Pediatr Nephrol. 2001.
  12. PMID 22116707 — Verbalis JG. Diabetes insipidus. Rev Endocr Metab Disord. 2003.

Back to Table of Contents

Connections

Back to Table of Contents